

Durable Remissions with Ivosidenib in *IDH1*-Mut

New England Journal of Medicine

378, 2386-2398

DOI: [10.1056/nejmoa1716984](https://doi.org/10.1056/nejmoa1716984)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 926-957.	2.3	451
3	Clinical Efficacy of a Novel Therapeutic Principle, Anakinosis. Frontiers in Pharmacology, 2018, 9, 1357.	1.6	26
4	Treatments targeting MDS genetics: a fool's errand?. Hematology American Society of Hematology Education Program, 2018, 2018, 277-285.	0.9	5
5	Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?. Drugs, 2018, 78, 1873-1885.	4.9	1
6	The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Review of Molecular Diagnostics, 2018, 18, 1041-1051.	1.5	34
7	Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells. Frontiers in Pharmacology, 2018, 9, 1258.	1.6	13
8	Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. Haematologica, 2018, 103, 1758-1759.	1.7	5
9	Novel Agents for Acute Myeloid Leukemia. Cancers, 2018, 10, 429.	1.7	21
10	Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy. OncoTargets and Therapy, 2019, Volume 12, 303-308.	1.0	13
11	The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia. OncoTargets and Therapy, 2018, Volume 11, 8265-8272.	1.0	27
12	Toward the potential cure of leukemias in the next decade. Cancer, 2018, 124, 4301-4313.	2.0	36
13	Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. Biochemical Journal, 2018, 475, 3221-3238.	1.7	10
14	Leveraging Hypomethylating Agents for Better MDS Therapy. Current Hematologic Malignancy Reports, 2018, 13, 507-515.	1.2	0
15	Is there a standard of care for relapsed AML?. Best Practice and Research in Clinical Haematology, 2018, 31, 384-386.	0.7	18
16	S100 Proteins in Acute Myeloid Leukemia. Neoplasia, 2018, 20, 1175-1186.	2.3	23
17	Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2018, 19, 3325.	1.8	46
18	Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Journal of Biological Chemistry, 2018, 293, 20051-20061.	1.6	11
19	Incorporating newer agents in the treatment of acute myeloid leukemia. Leukemia Research, 2018, 74, 113-120.	0.4	9

#	ARTICLE	IF	CITATIONS
20	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	7.7	138
21	Acute myeloid leukemia: 2019 update on risk stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 1267-1291.	2.0	283
22	How I treat the blast phase of Philadelphia chromosome negative myeloproliferative neoplasms. <i>Blood</i> , 2018, 132, 2339-2350.	0.6	27
23	SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 769-772.	0.2	16
24	Potent immunosuppressive effects of the oncometabolite <i>R</i> -2-hydroxyglutarate. <i>Oncolmmunology</i> , 2018, 7, e1528815.	2.1	16
25	Targeting dihydroorotate dehydrogenase in acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 1415-1417.	1.7	5
26	Ivosidenib in <i>IDH1</i> -Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 379, 1186-1186.	13.9	19
27	Ivosidenib: First Global Approval. <i>Drugs</i> , 2018, 78, 1509-1516.	4.9	113
28	Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. <i>Leukemia Research</i> , 2018, 73, 58-66.	0.4	47
29	The complexity of stem cell transplants: can we improve our understanding?. <i>Haematologica</i> , 2018, 103, 1417-1418.	1.7	0
30	AML: Next Questions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S64-S65.	0.2	0
31	Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy. <i>Blood Advances</i> , 2018, 2, 2787-2797.	2.5	20
32	Managing myelofibrosis (MF) that "œblasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 118-126.	0.9	9
33	When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 35-44.	0.9	22
34	New drugs for acute myeloid leukemia inspired by genomics and when to use them. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 45-50.	0.9	38
35	When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. <i>Blood Advances</i> , 2018, 2, 3070-3080.	2.5	36
36	Metabolic Signaling to the Nucleus in Cancer. <i>Molecular Cell</i> , 2018, 71, 398-408.	4.5	147
37	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	2.2	66

#	ARTICLE	IF	CITATIONS
38	Ivosidenib effective in IDH1-mutant AML. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 472-472.	12.5	7
39	Genetic and epigenetic determinants of AML pathogenesis. <i>Seminars in Hematology</i> , 2019, 56, 84-89.	1.8	65
40	DNA methylation as a transcriptional regulator of the immune system. <i>Translational Research</i> , 2019, 204, 1-18.	2.2	102
42	Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?. <i>Haematologica</i> , 2019, 104, 1521-1531.	1.7	18
44	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2019, 25, 258-272.e9.	5.2	60
45	Molecular landscape in adult acute myeloid leukemia: where we are where we going?. <i>Journal of Laboratory and Precision Medicine</i> , 0, 4, 17-17.	1.1	2
46	Novel therapies in low- and high-risk myelodysplastic syndrome. <i>Expert Review of Hematology</i> , 2019, 12, 893-908.	1.0	13
47	Metabolic Plasticity of Acute Myeloid Leukemia. <i>Cells</i> , 2019, 8, 805.	1.8	103
48	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265.	2.0	56
50	Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. <i>BMC Biology</i> , 2019, 17, 57.	1.7	31
51	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	3.7	161
52	Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986064.	1.1	90
53	<p>IDH1-mutated relapsed or refractory AML: current challenges and future prospects</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 19-32.	1.2	24
54	Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients. <i>Current Oncology Reports</i> , 2019, 21, 71.	1.8	13
55	Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention. <i>F1000Research</i> , 2019, 8, 590.	0.8	6
56	Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 989-1001.	1.9	43
57	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. <i>Drug Resistance Updates</i> , 2019, 47, 100646.	6.5	81
58	Iso citrate dehydrogenase inhibitors in acute myeloid leukemia. <i>Biomarker Research</i> , 2019, 7, 22.	2.8	73

#	ARTICLE	IF	CITATIONS
59	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. <i>Annals of Hematology</i> , 2019, 98, 2467-2483.	0.8	9
60	Metabolic dependencies and vulnerabilities in leukemia. <i>Genes and Development</i> , 2019, 33, 1460-1474.	2.7	63
61	Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. <i>Cancers</i> , 2019, 11, 1660.	1.7	11
62	Myeloid Gene Panel Testing with Correlation to Updated Clinical Practice Guidelines. <i>Advances in Molecular Pathology</i> , 2019, 2, 65-75.	0.2	0
63	Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 207.	1.8	32
64	The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 1162.	1.3	25
66	New drugs approved for acute myeloid leukaemia in 2018. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2689-2693.	1.1	39
67	Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1625.	1.7	19
68	Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071988282.	1.1	52
69	Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1581-1585.	2.5	57
70	<p>A personalized approach to acute myeloid leukemia therapy: current options</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 167-179.	0.4	7
71	Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. <i>Cells</i> , 2019, 8, 967.	1.8	43
72	Insights into novel emerging epigenetic drugs in myeloid malignancies. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986608.	1.1	6
73	Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 850.	1.3	15
74	Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. <i>Blood</i> , 2019, 134, 1487-1497.	0.6	95
75	IDH Inhibitors in AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S7-S9.	0.2	2
76	Recent drug approvals for acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 100.	6.9	97
77	Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 835-849.	1.9	41

#	ARTICLE	IF	CITATIONS
78	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. <i>Cancers</i> , 2019, 11, 1364.	1.7	23
79	Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. <i>Frontiers in Pediatrics</i> , 2019, 7, 401.	0.9	27
80	Non-allogeneic immunotherapy in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2019, 6, e443-e444.	2.2	0
81	Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. <i>Future Oncology</i> , 2019, 15, 3197-3208.	1.1	23
82	FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation. <i>Clinical Cancer Research</i> , 2019, 25, 3205-3209.	3.2	94
83	Treatment of MDS. <i>Blood</i> , 2019, 133, 1096-1107.	0.6	167
85	Metabolic Regulation of the Epitranscriptome. <i>ACS Chemical Biology</i> , 2019, 14, 316-324.	1.6	19
86	Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. <i>Frontiers in Oncology</i> , 2019, 9, 417.	1.3	183
87	Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. <i>Science Advances</i> , 2019, 5, eaaw4543.	4.7	98
88	From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. <i>Drugs</i> , 2019, 79, 1177-1186.	4.9	8
89	Sulfur metabolism and its contribution to malignancy. <i>International Review of Cell and Molecular Biology</i> , 2019, 347, 39-103.	1.6	40
90	Acute Myeloid Leukemia Mutations: Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2721.	1.8	17
91	Emerging Applications of Metabolomics in Clinical Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 544-556.	2.3	73
92	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.2	12
93	Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?. <i>Journal of Oncology Practice</i> , 2019, 15, 315-320.	2.5	3
94	Topoisomerase II inhibitors in AML: past, present, and future. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1637-1644.	0.9	25
95	Healthcare expenses for treatment of acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 641-650.	1.0	14
96	<p><p>MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)<p><p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2903-2910.	1.0	67

#	ARTICLE	IF	CITATIONS
97	Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1099-1108.	0.8	28
98	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 411-420.	1.8	16
99	Novel Therapeutics Affecting Metabolic Pathways. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e79-e87.	1.8	9
100	Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made. <i>Lancet Haematology</i> , 2019, 6, e290-e291.	2.2	5
101	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 171-178.	1.2	20
102	Management of myelodysplastic syndromes after failure of response to hypomethylating agents. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984705.	1.1	29
103	Evolutionary trajectory of leukemic clones and its clinical implications. <i>Haematologica</i> , 2019, 104, 872-880.	1.7	17
104	Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. <i>Leukemia Research</i> , 2019, 81, 43-49.	0.4	4
105	Downregulation of CD73 associates with T cell exhaustion in AML patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 40.	6.9	25
106	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 4231-4237.	3.2	30
107	Immunometabolism: A new target for improving cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 195-253.	1.9	30
108	Modeling Cancer with Flies and Fish. <i>Developmental Cell</i> , 2019, 49, 317-324.	3.1	68
109	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. <i>Blood Reviews</i> , 2019, 36, 70-87.	2.8	484
110	New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1983.	1.8	68
111	Clinical update on hypomethylating agents. <i>International Journal of Hematology</i> , 2019, 110, 161-169.	0.7	43
112	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019, 167, 133-148.	2.0	19
113	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 6-13.	2.0	16
114	Chromatin Bottlenecks in Cancer. <i>Trends in Cancer</i> , 2019, 5, 183-194.	3.8	9

#	ARTICLE	IF	CITATIONS
115	Characterization of the nicotinamide adenine dinucleotides (NAD ⁺ and NADP ⁺) binding sites of the monomeric isocitrate dehydrogenases from <i>Campylobacter</i> species. <i>Biochimie</i> , 2019, 160, 148-155.	1.3	4
116	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 494-507.	12.5	80
117	Long-term molecular remission in a patient with acute myeloid leukemia harboring a new <i>NUP98-LEDGF</i> rearrangement. <i>Cancer Medicine</i> , 2019, 8, 1765-1770.	1.3	5
118	Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. <i>Current Oncology Reports</i> , 2019, 21, 35.	1.8	5
119	Emerging Therapies for Acute Myelogenous Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. <i>Cancers</i> , 2019, 11, 260.	1.7	28
120	Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 425-441.	12.5	452
121	Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity. <i>Frontiers in Genetics</i> , 2019, 10, 133.	1.1	58
122	New drugs creating new challenges in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 903-914.	1.5	39
123	Treatment of myelodysplastic syndrome in the era of next-generation sequencing. <i>Journal of Internal Medicine</i> , 2019, 286, 41-62.	2.7	13
124	Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. <i>Leukemia and Lymphoma</i> , 2019, 60, 2635-2645.	0.6	6
125	Getting personal with myelodysplastic syndromes: is now the right time?. <i>Expert Review of Hematology</i> , 2019, 12, 215-224.	1.0	9
126	Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. <i>Cancer Treatment Reviews</i> , 2019, 75, 52-61.	3.4	21
127	Clonal hematopoiesis and preleukemia—Genetics, biology, and clinical implications. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 828-838.	1.5	18
128	Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3+7?. <i>Hematological Oncology</i> , 2019, 37, 558-563.	0.8	11
129	Overview of DNA methylation in adult diffuse gliomas. <i>Brain Tumor Pathology</i> , 2019, 36, 84-91.	1.1	45
130	The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. <i>Leukemia</i> , 2019, 33, 2403-2415.	3.3	138
131	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 803-811.	2.0	51
132	Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 160-166.	0.3	1

#	ARTICLE	IF	CITATIONS
133	Next Generation Sequencing in AML – On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. <i>Cancers</i> , 2019, 11, 252.	1.7	44
134	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 104-113.	0.7	5
135	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071881669.	1.1	71
136	IDH2 inhibition: another piece to the puzzle. <i>Blood</i> , 2019, 133, 625-626.	0.6	2
137	Outpatient induction and consolidation care strategies in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2019, 26, 65-70.	1.2	14
138	Progress in the problem of relapsed or refractory acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2019, 26, 88-95.	1.2	17
139	Shifting paradigms in the treatment of older adults with AML. <i>Seminars in Hematology</i> , 2019, 56, 110-117.	1.8	17
140	What are the most promising new agents in myelodysplastic syndromes?. <i>Current Opinion in Hematology</i> , 2019, 26, 77-87.	1.2	2
141	Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 224.	1.7	46
142	Pharmacokinetics, absorption, metabolism, and excretion of [¹⁴ C]ivosidenib (AG-120) in healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 837-848.	1.1	15
144	MRD evaluation of AML in clinical practice: are we there yet?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 557-569.	0.9	27
145	Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 242-255.	2.5	38
146	Epigenetic therapies in acute myeloid leukemia: where to from here?. <i>Blood</i> , 2019, 134, 1891-1901.	0.6	36
147	Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. <i>Scientific Reports</i> , 2019, 9, 16775.	1.6	14
148	The Graft-Versus-Leukemia Effect in AML. <i>Frontiers in Oncology</i> , 2019, 9, 1217.	1.3	75
149	Acute Leukemia: Diagnosis and Treatment. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150950.	0.7	19
150	Which novel agents hold the greatest promise in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101106.	0.7	2
151	The Important Role of Immunotherapies in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 2054.	1.0	5

#	ARTICLE	IF	CITATIONS
152	Novel Therapies in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150955.	0.7	9
153	Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150957.	0.7	6
154	Shared Decision-making in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150958.	0.7	11
155	Mutation-Driven Therapy in MDS. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 550-560.	1.2	4
156	Clinical value of new drugs in acute myeloid leukemia. <i>HemaSphere</i> , 2019, 3, 6-8.	1.2	0
157	Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?. <i>Frontiers in Immunology</i> , 2019, 10, 3004.	2.2	18
158	Application of Genomics to Clinical Practice in Haematological Malignancy. <i>Current Genetic Medicine Reports</i> , 2019, 7, 236-252.	1.9	0
159	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. <i>Genes</i> , 2019, 10, 1026.	1.0	26
160	The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6003.	1.8	92
161	Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2019, 26, 51-57.	1.2	4
162	Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1205.	1.3	29
163	What's new in consolidation therapy in AML?. <i>Seminars in Hematology</i> , 2019, 56, 96-101.	1.8	10
164	Maintenance therapy in acute myeloid leukemia: What is the future?. <i>Seminars in Hematology</i> , 2019, 56, 102-109.	1.8	11
165	Clinical implications of molecular markers in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 20-35.	1.1	44
166	Toward personalized treatment in multiple myeloma based on molecular characteristics. <i>Blood</i> , 2019, 133, 660-675.	0.6	136
167	Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 1-8.	0.2	9
168	Advances in patient care through increasingly individualized therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 73-74.	12.5	33
169	Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2019, 60, 1354-1369.	0.6	23

#	ARTICLE	IF	CITATIONS
170	IDH1-R132 changes vary according to NPM1 and other mutations status in AML. <i>Leukemia</i> , 2019, 33, 1043-1047.	3.3	17
171	Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 228.	1.8	93
172	An update on treatment of higher risk myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2019, 12, 61-70.	1.0	1
173	Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. <i>Blood Reviews</i> , 2019, 34, 26-33.	2.8	38
174	Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic. <i>Cancer Reports</i> , 2019, 2, e1131.	0.6	8
175	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. , 2019, , 1-18.		1
176	Management of primary refractory acute myeloid leukemia in the era of targeted therapies. <i>Leukemia and Lymphoma</i> , 2019, 60, 583-597.	0.6	10
177	<i>HNF4β</i> pathway mapping identifies wild-type <i>IDH1</i> as a targetable metabolic node in gastric cancer. <i>Gut</i> , 2020, 69, 231-242.	6.1	27
178	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444.	1.2	69
179	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. <i>Leukemia</i> , 2020, 34, 416-426.	3.3	13
180	Combining epigenetic drugs with other therapies for solid tumours – past lessons and future promise. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 91-107.	12.5	283
181	Outcome of relapsed/refractory AML patients with IDH1 ^{R132} mutations in real life before the era of IDH1 inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 473-476.	0.6	2
182	Mutational profiling in myelofibrosis: implications for management. <i>International Journal of Hematology</i> , 2020, 111, 192-199.	0.7	9
183	The Mitochondrion as an Emerging Therapeutic Target in Cancer. <i>Trends in Molecular Medicine</i> , 2020, 26, 119-134.	3.5	121
184	Diverse pathogenetic roles of SOX genes in acute myeloid leukaemia and their therapeutic implications. <i>Seminars in Cancer Biology</i> , 2020, 67, 24-29.	4.3	3
185	JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 40, 100634.	2.8	32
186	Clonal Hematopoiesis and Premalignant Diseases. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035675.	2.9	10
187	Recently approved molecularly targeted therapies in AML. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e76.	0.6	0

#	ARTICLE	IF	CITATIONS
188	How we manage adults with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2020, 189, 1016-1027.	1.2	60
189	Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. <i>Cancers</i> , 2020, 12, 120.	1.7	39
190	Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?. <i>Expert Review of Hematology</i> , 2020, 13, 99-108.	1.0	3
191	The minimal that kills: Why defining and targeting measurable residual disease is the <i>â€œSine Qua Nonâ€</i> for further progress in management of acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 43, 100650.	2.8	17
192	Prospects for Venetoclax in Myelodysplastic Syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 441-448.	0.9	11
193	Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity. <i>Biochemistry</i> , 2020, 59, 479-490.	1.2	4
194	2-Hydroxyglutarate in Cancer Cells. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 903-926.	2.5	68
195	Real-time NMR Spectroscopy for Studying Metabolism. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 2304-2308.	7.2	31
196	Prevention of relapse after allogeneic stem cell transplantation in acute myeloid leukemia: Updates and challenges. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e77.	0.6	3
197	Targeting Cell Metabolism as Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 285-308.	2.5	32
198	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. <i>Nature Reviews Cancer</i> , 2020, 20, 158-173.	12.8	181
199	Relapsed or primary refractory AML: moving past MEC and FLAG-ida. <i>Current Opinion in Hematology</i> , 2020, 27, 108-114.	1.2	19
200	Targeting epigenetic regulators in the treatment of T-cell lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 127-139.	1.0	8
201	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 74.	1.7	21
202	The face of remission induction. <i>British Journal of Haematology</i> , 2020, 188, 101-115.	1.2	3
203	Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFI ² 1/p-Smad2/3 signaling. <i>Cancer Letters</i> , 2020, 472, 151-164.	3.2	43
204	Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 1-13.	1.6	21
205	Blockade of Glutathione Metabolism in <i>IDH1</i> -Mutated Glioma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 221-230.	1.9	55

#	ARTICLE	IF	CITATIONS
206	Hypomethylating agent based combinations in higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2020, 61, 1012-1027.	0.6	2
207	Real-time NMR Spectroscopy for Studying Metabolism. <i>Angewandte Chemie</i> , 2020, 132, 2324-2328.	1.6	9
208	Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e66-e75.	0.2	10
209	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 1273-1283.	0.8	281
210	Hypomethylating agents with venetoclax. <i>Current Opinion in Hematology</i> , 2020, 27, 76-80.	1.2	3
211	AML through the prism of molecular genetics. <i>British Journal of Haematology</i> , 2020, 188, 49-62.	1.2	17
212	Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions. <i>Current Oncology Reports</i> , 2020, 22, 125.	1.8	17
213	The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6830.	1.8	11
214	A precision medicine approach to management of acute myeloid leukemia in older adults. <i>Current Opinion in Oncology</i> , 2020, 32, 650-655.	1.1	3
215	Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 387-397.	2.5	4
216	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. <i>Cells</i> , 2020, 9, 2310.	1.8	37
217	2-Oxoglutarate-dependent dioxygenases in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 710-726.	12.8	119
218	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
219	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 96, 106420.	0.4	3
220	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. <i>Leukemia</i> , 2020, 34, 2552-2560.	3.3	9
221	AML: Veränderte Therapielandschaft in optimale Versorgung umsetzen. <i>Karger Kompass Onkologie</i> , 2020, 7, 56-57.	0.0	0
222	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1989-2007.	0.8	26
223	Current Understandings of Myeloid Differentiation Inducers in Leukemia Therapy. <i>Acta Haematologica</i> , 2021, 144, 380-388.	0.7	11

#	ARTICLE	IF	CITATIONS
224	Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Oncology</i> , 2020, 10, 596134.	1.3	13
225	Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials. <i>Lancet Haematology</i> , 2020, 7, 853-856.	2.2	2
226	Emerging treatment options for patients with high-risk myelodysplastic syndrome. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	1.1	19
227	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 421-428.	0.4	3
228	<p>Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12367-12382.	1.0	39
229	Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 57-66.	0.9	13
230	Therapy for lower-risk MDS. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 426-433.	0.9	31
231	Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML. <i>Biomarker Research</i> , 2020, 8, 65.	2.8	6
232	Treating acute myeloid leukemia in the modern era: A primer. <i>Cancer</i> , 2020, 126, 4668-4677.	2.0	18
233	The role of mitochondrial proteases in leukemic cells and leukemic stem cells. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1481-1487.	1.6	8
234	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. , 2020, , 343-360.		0
235	The epigenomics of sarcoma. <i>Nature Reviews Cancer</i> , 2020, 20, 608-623.	12.8	121
236	Epigenetic Therapies for Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 650-663.	13.9	289
237	Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. <i>Journal of Biomedical Science</i> , 2020, 27, 81.	2.6	35
238	Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. <i>Biomedicines</i> , 2020, 8, 245.	1.4	35
239	Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5114.	1.8	5
240	Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, <i>IDH1</i>-mutant glioblastoma: a case report from a Phase I study. <i>CNS Oncology</i> , 2020, 9, CNS62.	1.2	21
241	Clinical outcomes of IDH2 -mutated advanced-phase Phase-negative myeloproliferative neoplasms treated with enasidenib. <i>British Journal of Haematology</i> , 2020, 190, e48-e51.	1.2	30

#	ARTICLE	IF	CITATIONS
242	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 1399-1420.	2.0	119
243	Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 791-796.	0.2	6
244	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. <i>Leukemia</i> , 2020, 34, 2903-2913.	3.3	38
245	Reduced-intensity versus Myeloablative Conditioning Regimens for Younger Adults with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A systematic review and meta-analysis. <i>Journal of Cancer</i> , 2020, 11, 5223-5235.	1.2	5
247	Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 619-632.	1.1	9
248	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	15.2	104
249	Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome. <i>Drug Resistance Updates</i> , 2020, 53, 100730.	6.5	22
250	Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 429-438.	0.4	2
251	Outcome of patients with IDH1/2-mutated post-relapse myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	2.5	37
252	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <i>Blood Cancer Journal</i> , 2020, 10, 107.	2.8	96
253	Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 3342.	1.0	11
254	Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). <i>American Journal of Clinical Pathology</i> , 2020, 154, 731-741.	0.4	22
255	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. <i>Expert Review of Hematology</i> , 2020, 13, 1131-1142.	1.0	8
256	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <i>Expert Review of Hematology</i> , 2020, 13, 1057-1065.	1.0	5
257	Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a035477.	2.9	2
258	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , 2020, 61, 3287-3305.	0.6	2
259	Epigenomic Reprogramming as a Driver of Malignant Glioma. <i>Cancer Cell</i> , 2020, 38, 647-660.	7.7	66
260	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect-MDS/AML Disease Registry. <i>EJHaem</i> , 2020, 1, 58-68.	0.4	5

#	ARTICLE	IF	CITATIONS
261	IDH Inhibition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S3-S4.	0.2	0
262	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
263	Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias. <i>Cancers</i> , 2020, 12, 2427.	1.7	13
264	Metabolic Constrains Rule Metastasis Progression. <i>Cells</i> , 2020, 9, 2081.	1.8	13
265	Evaluating ivosidenib for the treatment of acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2205-2213.	0.9	9
266	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. <i>Biomedicines</i> , 2020, 8, 294.	1.4	39
267	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 288.	7.1	98
268	Cardiotoxicity of Novel Targeted Hematological Therapies. <i>Life</i> , 2020, 10, 344.	1.1	20
269	A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN. <i>Blood Advances</i> , 2020, 4, 6034-6038.	2.5	4
270	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. <i>Frontiers in Oncology</i> , 2020, 10, 599933.	1.3	15
271	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	2.5	29
272	Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development. <i>Cancers</i> , 2020, 12, 3225.	1.7	52
273	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 562558.	1.3	49
274	Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 942-948.	1.1	21
275	Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4280-4288.	3.2	58
276	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 1894-1905.	2.5	129
277	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. <i>Current Oncology Reports</i> , 2020, 22, 61.	1.8	21
278	Establishing specific response criteria for MDS/MPN - Getting closer to reality?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101170.	0.7	0

#	ARTICLE	IF	CITATIONS
279	Acute myeloid leukemia transformed to a targetable disease. <i>Future Oncology</i> , 2020, 16, 961-972.	1.1	12
280	Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. <i>Nature Reviews Cancer</i> , 2020, 20, 365-382.	12.8	87
281	The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients. <i>Diagnostics</i> , 2020, 10, 263.	1.3	3
282	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	5.1	620
283	Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 187, 113353.	1.4	12
284	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged ≤ 60 years. <i>Leukemia</i> , 2020, 34, 3215-3227.	3.3	66
285	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23
286	Leukemia secondary to myeloproliferative neoplasms. <i>Blood</i> , 2020, 136, 61-70.	0.6	80
287	IDH-Mutant Gliomas. , 2020, , .		4
288	Lower Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 21.	2.0	68
289	Advances in targeted therapy for acute myeloid leukemia. <i>Biomarker Research</i> , 2020, 8, 17.	2.8	41
290	Ivosidenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	0.8	167
291	Novel therapeutic strategies for MLL-rearranged leukemias. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2020, 1863, 194584.	0.9	8
292	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.2	10
293	Novel Treatment Paradigms in Acute Myeloid Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 506-514.	2.3	12
294	Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. <i>Blood Reviews</i> , 2020, 42, 100708.	2.8	10
295	Implications of Clonal Hematopoiesis for Precision Oncology. <i>JCO Precision Oncology</i> , 2020, 4, 639-646.	1.5	16
296	Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 792.	1.3	24

#	ARTICLE	IF	CITATIONS
297	Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. <i>Annals of Hematology</i> , 2020, 99, 1429-1440.	0.8	33
298	How I treat relapsed or refractory AML. <i>Blood</i> , 2020, 136, 1023-1032.	0.6	64
299	Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML. <i>Clinical Cancer Research</i> , 2020, 26, 4174-4176.	3.2	5
300	Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. <i>Cancer Medicine</i> , 2020, 9, 3371-3382.	1.3	7
301	Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2020, 12, e10895.	3.3	14
302	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. <i>Lancet Haematology</i> , 2020, 7, e309-e319.	2.2	70
303	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet</i> , 2020, 395, 1078-1088.	6.3	302
304	Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 96-103.	1.8	6
305	Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091301.	1.1	18
306	IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 431-437.	0.3	1
307	Metabolism of pancreatic cancer: paving the way to better anticancer strategies. <i>Molecular Cancer</i> , 2020, 19, 50.	7.9	192
308	Requirement for LIM kinases in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 3173-3185.	3.3	8
309	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. <i>Translational Oncology</i> , 2020, 13, 100780.	1.7	0
310	Treatment of Relapsed Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 66.	1.3	138
311	SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?. <i>Frontiers in Oncology</i> , 2020, 10, 1024.	1.3	3
312	Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1892.	1.0	11
313	Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2125-2139.	5.7	15
314	Epigenetic activation of O-linked N ² -acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. <i>EBioMedicine</i> , 2020, 54, 102678.	2.7	10

#	ARTICLE	IF	CITATIONS
315	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. <i>Leukemia and Lymphoma</i> , 2020, 61, 1418-1427.	0.6	16
316	Venetoclax in acute myeloid leukemia – current and future directions. <i>Leukemia and Lymphoma</i> , 2020, 61, 1313-1322.	0.6	31
317	An evaluation of glasdegib for the treatment of acute myelogenous leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 523-530.	0.9	15
318	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 357.	1.7	11
319	The Time Has Come for Targeted Therapies for AML: Lights and Shadows. <i>Oncology and Therapy</i> , 2020, 8, 13-32.	1.0	32
320	Driver mutations in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 49-57.	1.2	44
321	A User’s Guide to Novel Therapies for Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 277-288.	0.2	17
322	AML: New Drugs but New Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 341-350.	0.2	23
323	Treatment of Acquired Sideroblastic Anemias. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 401-420.	0.9	3
324	The Clinical Management of Clonal Hematopoiesis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 357-367.	0.9	42
325	Novel therapies in myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2020, 27, 58-65.	1.2	4
326	How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. <i>Future Oncology</i> , 2020, 16, 281-291.	1.1	7
327	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. <i>Leukemia Research</i> , 2020, 91, 106339.	0.4	20
328	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. <i>Leukemia and Lymphoma</i> , 2020, 61, 1455-1464.	0.6	4
329	Interaction between IDH1 WT and calmodulin and its implications for glioblastoma cell growth and migration. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 224-230.	1.0	8
330	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 8.	6.9	16
331	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	1.7	12
332	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. <i>Current Molecular Biology Reports</i> , 2020, 6, 1-9.	0.8	20

#	ARTICLE	IF	CITATIONS
333	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1751-1759.	3.3	18
334	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. <i>Cancer Discovery</i> , 2020, 10, 506-525.	7.7	212
335	Updates on DNA methylation modifiers in acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 693-701.	0.8	16
336	Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1200-1212.	0.5	4
337	How we treat older patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 682-691.	1.2	3
338	Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 697-712.	0.6	164
339	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. <i>Blood Reviews</i> , 2020, 44, 100679.	2.8	26
340	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2907.	1.8	158
341	<i>IDH1</i> and <i>IDH2</i> mutations in lung adenocarcinomas: Evidences of subclonal evolution. <i>Cancer Medicine</i> , 2020, 9, 4386-4394.	1.3	18
342	Synthetic Approaches to New Drugs Approved during 2018. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10652-10704.	2.9	33
343	Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. <i>Targeted Oncology</i> , 2020, 15, 147-162.	1.7	27
344	Emerging pharmacotherapies for elderly acute myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2020, 13, 619-643.	1.0	7
345	Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 34.	1.3	2
346	Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1415-1417.	0.8	2
347	Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 959-968.	1.1	15
348	Surface plasma Ag-decorated Bi5O7I microspheres uniformly distributed on a zwitterionic fluorinated polymer with superfunctional antifouling property. <i>Applied Catalysis B: Environmental</i> , 2020, 271, 118920.	10.8	46
349	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14
350	How I treat acute myeloid leukemia in the era of new drugs. <i>Blood</i> , 2020, 135, 85-96.	0.6	172

#	ARTICLE	IF	CITATIONS
351	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 135, 463-471.	0.6	266
352	Gilteritinib: potent targeting of FLT3 mutations in AML. <i>Blood Advances</i> , 2020, 4, 1178-1191.	2.5	86
353	Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper. <i>Blood Advances</i> , 2020, 4, 762-775.	2.5	24
354	Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 970-982.	2.5	16
355	Clinical implications of recurrent gene mutations in acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2020, 9, 4.	2.0	47
356	The Changing Landscape of Treatment in Acute Myeloid Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 343-354.	1.8	9
357	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720.	1.7	99
358	IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. <i>British Journal of Cancer</i> , 2020, 122, 1580-1589.	2.9	301
359	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 565-573.	1.7	29
360	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034975.	2.9	8
361	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	3.3	56
362	Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. <i>Internal Medicine</i> , 2021, 60, 15-23.	0.3	1
363	Sirtuin activation targets IDH-mutant tumors. <i>Neuro-Oncology</i> , 2021, 23, 53-62.	0.6	15
364	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis. <i>Leukemia</i> , 2021, 35, 1301-1316.	3.3	30
365	Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies. <i>European Journal of Haematology</i> , 2021, 106, 105-113.	1.1	8
366	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <i>Blood</i> , 2021, 137, 1792-1803.	0.6	123
367	Epigenetic Regulators as the Gatekeepers of Hematopoiesis. <i>Trends in Genetics</i> , 2021, 37, 125-142.	2.9	40
368	Evolving treatment patterns and outcomes in older patients (>60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585.	3.3	12

#	ARTICLE	IF	CITATIONS
369	Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2021, 62, 438-445.	0.6	5
370	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
371	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€†. <i>Annals of Oncology</i> , 2021, 32, 142-156.	0.6	75
372	<i>IDH1</i> mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis. <i>Blood</i> , 2021, 137, 945-958.	0.6	16
373	A basic review on systemic treatment options in WHO grade II-III gliomas. <i>Cancer Treatment Reviews</i> , 2021, 92, 102124.	3.4	44
374	CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. <i>Blood</i> , 2021, 137, 661-677.	0.6	103
375	A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia. <i>European Journal of Haematology</i> , 2021, 106, 260-266.	1.1	3
376	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021, 11, 1158-1175.	7.7	57
377	Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e415-e422.	0.2	3
378	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€” and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	2.0	10
379	Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 57-65.	0.8	118
380	Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 5-8.	1.1	3
381	Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 99-109.	0.8	4
382	Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 158-166.	0.6	10
383	Management of fever and neutropenia in the adult patient with acute myeloid leukemia. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 359-378.	2.0	9
384	Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 409-421.	0.6	7
385	Leukemia: Trends in treatment and how close we have achieved eradication. , 2021, , 547-587.		0
386	Acquired deficiency of peroxisomal dicarboxylic acid catabolism is a metabolic vulnerability in hepatoblastoma. <i>Journal of Biological Chemistry</i> , 2021, 296, 100283.	1.6	6

#	ARTICLE	IF	CITATIONS
387	Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 4.	6.9	47
388	Epigenetics in acute myeloid leukemia. , 2021, , 447-469.		0
389	Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110403.	1.1	4
390	Application of gene mutation analysis in hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Journal of Hematopoietic Cell Transplantation</i> , 2021, 10, 16-22.	0.1	0
391	Treatment of Relapsed and Refractory AML: Intensive Approach in Fit Patients. <i>Hematologic Malignancies</i> , 2021, , 233-240.	0.2	0
392	Mitochondrial and Metabolic Pathways Regulate Nuclear Gene Expression to Control Differentiation, Stem Cell Function, and Immune Response in Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1052-1066.	7.7	24
393	Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil. <i>Journal of Cancer</i> , 2021, 12, 4862-4872.	1.2	9
394	Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 664-670.	1.7	30
395	Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplant. , 2021, , 231-250.		0
397	Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. <i>Journal of Korean Medical Science</i> , 2021, 36, e85.	1.1	6
398	Future epigenetic treatment strategies. , 2021, , 103-119.		0
399	A review of FDA-approved acute myeloid leukemia therapies beyond $\hat{c}7 + 3\hat{c}TM$. <i>Expert Review of Hematology</i> , 2021, 14, 185-197.	1.0	30
400	Targeting Cancer Metabolism and Current Anti-Cancer Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1286, 15-48.	0.8	12
401	Future Developments: Novel Agents. <i>Hematologic Malignancies</i> , 2021, , 293-315.	0.2	1
402	Future Developments: Measurable Residual Disease. <i>Hematologic Malignancies</i> , 2021, , 317-337.	0.2	0
403	Concept and Optimal Treatments of Malignant Gliomas. <i>Japanese Journal of Neurosurgery</i> , 2021, 30, 374-379.	0.0	0
404	Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 493-507.	2.0	17
405	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations â€“ a registry based analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1432-1440.	0.6	7

#	ARTICLE	IF	CITATIONS
406	APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 403-416.	1.7	95
408	Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 97-111.	1.2	10
410	Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. <i>PLoS ONE</i> , 2021, 16, e0247093.	1.1	5
412	High <i>ROBO3</i> expression predicts poor survival in non-M3 acute myeloid leukemia. <i>Experimental Biology and Medicine</i> , 2021, 246, 1184-1197.	1.1	5
413	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	2.8	313
414	Applications of next-generation sequencing in hematologic malignancies. <i>Human Immunology</i> , 2021, 82, 859-870.	1.2	8
415	Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective. <i>Leukemia and Lymphoma</i> , 2021, 62, 779-790.	0.6	1
416	Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. <i>Diagnostics</i> , 2021, 11, 252.	1.3	2
417	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	2.5	18
418	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733.	3.2	33
419	Mutation-dependent treatment approaches for patients with complex multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 189-201.	0.4	0
420	Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. <i>Blood Advances</i> , 2021, 5, 900-912.	2.5	30
421	Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer. <i>Oncoscience</i> , 2021, 8, 1-13.	0.9	1
422	Two decades of targeted therapies in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 651-660.	3.3	33
423	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. <i>Leukemia Research</i> , 2021, 101, 106492.	0.4	0
425	A Perspective of Epigenetic Regulation in Radiotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 624312.	1.8	19
426	Prognostic significance of concurrent gene mutations in intensively treated patients with <i>IDH</i> -mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	0.6	36
427	Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future. <i>Journal of Geriatric Oncology</i> , 2021, 12, 980-984.	0.5	3

#	ARTICLE	IF	CITATIONS
428	Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment. <i>Current Oncology Reports</i> , 2021, 23, 22.	1.8	21
429	Clinical-grade whole-genome sequencing and 3â€² transcriptome analysis of colorectal cancer patients. <i>Genome Medicine</i> , 2021, 13, 33.	3.6	5
430	Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 479.e1-479.e7.	0.6	10
431	CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia. <i>Frontiers in Genetics</i> , 2020, 11, 600227.	1.1	6
432	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. <i>Cancers</i> , 2021, 13, 748.	1.7	8
433	Target Therapy in Acute Myeloid Leukemia. , 0, , .		0
434	Differentiation syndrome with lowerâ€”intensity treatments for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 735-746.	2.0	12
435	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. <i>Cancer</i> , 2021, 127, 1186-1207.	2.0	74
436	Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1568.	1.7	21
437	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	3.9	32
438	Harnessing the Metabolic Vulnerabilities of Leukemia Stem Cells to Eradicate Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 632789.	1.3	3
439	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	29
440	Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. <i>Cell Stem Cell</i> , 2021, 28, 378-393.	5.2	67
441	Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 626605.	1.3	2
442	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3135.	1.8	5
443	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 451-461.	1.9	6
444	Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream. <i>Hemato</i> , 2021, 2, 131-153.	0.2	3
445	Epidemiology of acute myeloid leukemia in Virginia: Excellent survival outcomes for patients in rural Appalachia. <i>Cancer Reports</i> , 2021, 4, e1354.	0.6	3

#	ARTICLE	IF	CITATIONS
446	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	1.3	39
447	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. <i>Molecular Cell</i> , 2021, 81, 922-939.e9.	4.5	157
448	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 328-350.	1.8	2
449	PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1. <i>Oncogene</i> , 2021, 40, 2448-2462.	2.6	19
450	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	56
451	Emerging agents and regimens for AML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 49.	6.9	104
452	Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 192-206.	1.2	11
453	Phase I study of ADI‑PEG20 plus low‑dose cytarabine for the treatment of acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 2946-2955.	1.3	14
454	Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101240.	0.7	0
455	New Treatment Options for Older Patients with Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2021, 22, 39.	1.3	10
456	Which novel agents will have a clinically meaningful impact in AML at diagnosis?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101257.	0.7	3
457	Mechanisms of Resistance of New Target Drugs in Acute Myeloid Leukemia. , 0, , .		0
458	Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 340-356.	5.7	11
459	Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. <i>Leukemia</i> , 2021, 35, 3278-3281.	3.3	10
460	Clinical cancer genomic profiling. <i>Nature Reviews Genetics</i> , 2021, 22, 483-501.	7.7	79
461	Precision medicine in myeloid malignancies. <i>Seminars in Cancer Biology</i> , 2022, 84, 153-169.	4.3	18
462	Taking aim at IDH in fitter patients with AML. <i>Blood</i> , 2021, 137, 1706-1707.	0.6	0
463	Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 666091.	1.3	11

#	ARTICLE	IF	CITATIONS
464	IDH Inhibitors in AML—Promise and Pitfalls. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 207-217.	1.2	33
465	Targeting pan-essential genes in cancer: Challenges and opportunities. <i>Cancer Cell</i> , 2021, 39, 466-479.	7.7	88
466	Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. <i>Pathology</i> , 2021, 53, 328-338.	0.3	6
467	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 203-215.	0.4	2
468	Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique. <i>Annals of Hematology</i> , 2021, 100, 1983-1993.	0.8	2
469	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
470	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 301-307.	1.9	5
471	Assessing acquired resistance to IDH1 inhibitor therapy by full-exon <i>IDH1</i> sequencing and structural modeling. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006007.	0.5	10
472	Advances in epigenetic therapeutics with focus on solid tumors. <i>Clinical Epigenetics</i> , 2021, 13, 83.	1.8	53
473	Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 1684.	1.0	19
474	SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 266-287.	2.6	37
475	Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS). <i>Hemato</i> , 2021, 2, 217-236.	0.2	2
476	How I Treat Adult Acute Myeloid Leukemia. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 182-189.	0.1	1
477	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. <i>Blood Advances</i> , 2021, 5, 2279-2283.	2.5	2
478	<i>IDH1</i> and <i>IDH2</i> Mutations in Colorectal Cancers. <i>American Journal of Clinical Pathology</i> , 2021, 156, 777-786.	0.4	12
479	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	2.0	79
480	An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 407-417.	1.0	0
481	Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 678824.	1.3	5

#	ARTICLE	IF	CITATIONS
482	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 2607.	5.8	61
483	Acute myeloid leukaemia in patients we judge as being older and/or unfit. <i>Journal of Internal Medicine</i> , 2021, 290, 279-293.	2.7	7
484	The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 665291.	1.3	5
485	Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5789.	1.8	6
486	From Bench to Bedside. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 213-221.	1.0	1
487	From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5574.	1.8	6
488	Enasidenib-induced Sweet syndrome with differentiation syndrome. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04099.	0.2	3
490	Towards precision medicine for AML. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 577-590.	12.5	138
491	Metabolomics in cancer research and emerging applications in clinical oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 333-358.	157.7	267
492	A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat <i>versus</i> low-dose ara-C in older patients with acute myeloid leukaemia: results of the L1 trial. <i>British Journal of Haematology</i> , 2021, 194, 298-308.	1.2	6
493	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. <i>Frontiers in Immunology</i> , 2021, 12, 659595.	2.2	44
494	Advances in Management for Older Adults With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 2102-2114.	0.8	24
495	Focus on Novel Therapies for Older Adults with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes. <i>Advances in Oncology</i> , 2021, 1, 237-248.	0.1	1
496	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 201.	7.1	607
497	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2510-2517.	1.3	9
498	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	6.9	10
499	Disruption of a GATA2-TAL1-ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells. <i>Blood</i> , 2021, 138, 1441-1455.	0.6	26
500	Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia. <i>Oncotarget</i> , 2021, 12, 1314-1317.	0.8	1

#	ARTICLE	IF	CITATIONS
501	Epigenetic deregulation in myeloid malignancies. <i>Blood</i> , 2021, 138, 613-624.	0.6	8
502	Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. <i>Blood Cancer Journal</i> , 2021, 11, 107.	2.8	73
503	Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. <i>Cell Death Discovery</i> , 2021, 7, 137.	2.0	10
504	Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal. <i>Cancers</i> , 2021, 13, 3170.	1.7	6
505	Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions. <i>HemaSphere</i> , 2021, 5, e583.	1.2	6
506	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 41-54.	1.2	8
507	Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. <i>Future Oncology</i> , 2021, 17, 2057-2074.	1.1	14
508	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 457-473.	1.6	19
509	Treatment for Relapsed/Refractory Acute Myeloid Leukemia. <i>HemaSphere</i> , 2021, 5, e572.	1.2	26
510	Cancer cell metabolic plasticity in migration and metastasis. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 343-359.	1.7	44
511	Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers. <i>Cancers</i> , 2021, 13, 3230.	1.7	17
513	Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. <i>Cancer Medicine</i> , 2021, 10, 4250-4268.	1.3	2
514	The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. <i>Biomarker Research</i> , 2021, 9, 50.	2.8	9
515	Targeting Chromatin Regulation in Acute Myeloid Leukemia. <i>HemaSphere</i> , 2021, 5, e589.	1.2	1
516	Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia. <i>Cancers</i> , 2021, 13, 3175.	1.7	7
517	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	3.2	112
518	A precision medicine classification for treatment of acute myeloid leukemia in older patients. <i>Journal of Hematology and Oncology</i> , 2021, 14, 96.	6.9	5
519	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2021, 13, 3296.	1.7	4

#	ARTICLE	IF	CITATIONS
520	Mitochondrial metabolism: powering new directions in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2331-2341.	0.6	6
521	Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 927-931.	1.2	1
522	JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 129-141.	0.6	4
523	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1009-1018.	0.6	40
524	Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing. <i>British Journal of Haematology</i> , 2022, 196, 19-30.	1.2	2
525	The implications of IDH mutations for cancer development and therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 645-661.	12.5	155
526	Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-7.	0.6	1
527	Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation. <i>JCO Global Oncology</i> , 2021, 7, 1220-1232.	0.8	6
528	Rapid chiral discrimination of oncometabolite dl-2-hydroxyglutaric acid using derivatization and field asymmetric waveform ion mobility spectrometry/mass spectrometry. <i>Journal of Separation Science</i> , 2021, 44, 3489-3496.	1.3	7
529	IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?. <i>Biomedicines</i> , 2021, 9, 799.	1.4	37
530	Targeted Therapies in Rare Brain Tumours. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7949.	1.8	4
531	AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms. <i>Oncogene</i> , 2021, 40, 5665-5676.	2.6	18
532	The beginning of a new therapeutic era in acute myeloid leukemia. <i>EJHaem</i> , 2021, 2, 823-833.	0.4	3
533	Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2804-2812.	1.3	15
534	Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant IDH1 for Treatment of IDH1-Mutant Malignancies. <i>Drug Metabolism and Disposition</i> , 2021, 49, DMD-AR-2020-000234.	1.7	4
535	Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?. <i>Current Oncology Reports</i> , 2021, 23, 109.	1.8	3
536	The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. <i>Blood Reviews</i> , 2021, 48, 100806.	2.8	14
537	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-12.	0.6	9

#	ARTICLE	IF	CITATIONS
538	Current and emerging strategies for management of myelodysplastic syndromes. <i>Blood Reviews</i> , 2021, 48, 100791.	2.8	34
539	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). <i>Cancers</i> , 2021, 13, 4189.	1.7	6
540	Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era. <i>Cancer</i> , 2022, 128, 139-149.	2.0	5
541	Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 263.	3.5	4
542	The use of genetic tests to diagnose and manage patients with myeloproliferative and myelodysplastic neoplasms, and related disorders. <i>British Journal of Haematology</i> , 2021, 195, 338-351.	1.2	8
543	Targeting leukemia-specific dependence on the de novo purine synthesis pathway. <i>Leukemia</i> , 2022, 36, 383-393.	3.3	11
544	Updates on targeted therapies for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 316-328.	1.2	76
545	3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. <i>Current Oncology Reports</i> , 2021, 23, 120.	1.8	8
546	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. <i>Cells</i> , 2021, 10, 1962.	1.8	11
547	Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e649-e657.	0.2	0
548	Cardio-Oncology. <i>JACC Basic To Translational Science</i> , 2021, 6, 705-718.	1.9	21
549	Double Drop-Off Droplet Digital PCR. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 975-985.	1.2	10
550	Metabolomics, metabolic flux analysis and cancer pharmacology. , 2021, 224, 107827.		44
551	Black Disparities in Targeted Therapy Clinical Trials – A Call for Future Reset. <i>Journal of Education and Teaching in Emergency Medicine</i> , 2021, 7, 8-28.	0.0	1
552	Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1292-1305.	1.2	8
553	SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 1-16.	0.2	20
554	Acute myeloid leukemia: Therapy resistance and a potential role for tetraspanin membrane scaffolds. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 137, 106029.	1.2	7
555	Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?. <i>Cancers</i> , 2021, 13, 4121.	1.7	2

#	ARTICLE	IF	CITATIONS
556	Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes. <i>European Journal of Haematology</i> , 2021, 107, 609-616.	1.1	1
557	Novel Strategies in the Treatment of Older Patients with Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S51-S53.	0.2	0
558	Application of omics- and multi-omics-based techniques for natural product target discovery. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111833.	2.5	29
559	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	2.6	41
560	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. <i>Annals of Hematology</i> , 2021, 100, 3017-3027.	0.8	0
561	Detecting and preventing post-hematopoietic cell transplant relapse in AML. <i>Current Opinion in Hematology</i> , 2021, Publish Ahead of Print, 380-388.	1.2	0
562	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.2	28
563	Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias. <i>Cancers</i> , 2021, 13, 4887.	1.7	11
564	Small-Molecule Anti-Cancer Drugs From 2016 to 2020: Synthesis and Clinical Application. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110403.	0.2	2
565	SOHO State of the Art Updates and Next Questions: IDH Inhibition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 567-572.	0.2	0
566	Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4646.	1.7	8
567	Prognostic and predictive biomarker developments in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 151.	6.9	49
568	The changing landscape for patients with relapsed/refractory acute myeloid leukaemia. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 635-641.	1.1	4
569	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 751668.	1.3	2
570	AML and the art of remission maintenance. <i>Blood Reviews</i> , 2021, 49, 100829.	2.8	18
571	Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.. <i>Blood Advances</i> , 2021, 5, 4794-4805.	2.5	13
572	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.	0.6	17
573	Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. <i>Experimental Hematology and Oncology</i> , 2021, 10, 1.	2.0	17

#	ARTICLE	IF	CITATIONS
574	Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients. Hematologic Malignancies, 2021, , 241-254.	0.2	0
575	Genomic Landscape and Clonal Evolution of AML. Hematologic Malignancies, 2021, , 103-118.	0.2	0
576	The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia. Seminars in Hematology, 2021, 58, 56-65.	1.8	8
577	Secondary AML. Hematologic Malignancies, 2021, , 71-101.	0.2	0
578	Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia. Leukemia Research, 2021, 100, 106494.	0.4	1
579	Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1 mutant advanced hematologic malignancies. Clinical and Translational Science, 2021, 14, 942-953.	1.5	8
581	Advances in Research of Adult Gliomas. International Journal of Molecular Sciences, 2021, 22, 924.	1.8	27
582	Primary Central Nervous System Tumors. , 2020, , 295-325.		1
583	Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. Current Treatment Options in Oncology, 2020, 21, 8.	1.3	7
584	New Treatment Options for Acute Myeloid Leukemia in 2019. Current Oncology Reports, 2019, 21, 16.	1.8	49
585	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resistance Updates, 2020, 52, 100703.	6.5	25
586	Metabolomics in acute myeloid leukemia. Molecular Genetics and Metabolism, 2020, 130, 230-238.	0.5	27
587	Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy. Leukemia, 2021, 35, 417-432.	3.3	22
588	An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity. Biochemical Journal, 2020, 477, 2999-3018.	1.7	8
589	Novel therapies for AML: a round-up for clinicians. Expert Review of Clinical Pharmacology, 2020, 13, 1389-1400.	1.3	21
593	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood, 2020, 135, 2137-2145.	0.6	470
594	Single-agent and combination biologics in acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2019, 2019, 548-556.	0.9	22
595	Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Research, 2020, 9, 1091.	0.8	8

#	ARTICLE	IF	CITATIONS
596	Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors. <i>World Journal of Oncology</i> , 2019, 10, 226-230.	0.6	2
597	Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. <i>Oncotarget</i> , 2020, 11, 2233-2245.	0.8	4
598	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. , 2021, 4, 125-142.		26
599	Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. <i>Current Cancer Drug Targets</i> , 2020, 20, 490-500.	0.8	14
600	The Evolving AML Genomic Landscape: Therapeutic Implications. <i>Current Cancer Drug Targets</i> , 2020, 20, 532-544.	0.8	8
601	Enasidenib and ivosidenib in AML. <i>Minerva Medica</i> , 2020, 111, 411-426.	0.3	20
602	Management of AML Beyond $\text{FCM} + 7\text{A}$ in 2019. <i>Clinical Hematology International</i> , 2019, 1, 10.	0.7	9
603	Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Clinical Hematology International</i> , 2019, 1, 94-100.	0.7	5
604	Myelodysplastic syndromes: moving towards personalized management. <i>Haematologica</i> , 2020, 105, 1765-1779.	1.7	52
605	Differentiation therapy of myeloid leukemia: four decades of development. <i>Haematologica</i> , 2021, 106, 1-13.	1.7	27
606	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	1.7	63
607	Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits. <i>Ecancermedalscience</i> , 2020, 14, 1015.	0.6	3
608	Location First: Targeting Acute Myeloid Leukemia Within Its Niche. <i>Journal of Clinical Medicine</i> , 2020, 9, 1513.	1.0	22
609	Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications. <i>Biomedical Reports</i> , 2020, 13, 43-48.	0.9	15
610	The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies. <i>Balkan Medical Journal</i> , 2019, 36, 78-87.	0.3	3
611	New agents in acute myeloid leukemia (AML). <i>Blood Research</i> , 2020, 55, S14-S18.	0.5	16
612	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	2.3	314
613	Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 6-10.	2.3	5

#	ARTICLE	IF	CITATIONS
614	Advances in Epigenetic Cancer Therapeutics. <i>Cureus</i> , 2020, 12, e11725.	0.2	17
615	Current and Emerging Therapies for Acute Myeloid Leukemia. <i>Cancer Treatment and Research</i> , 2021, 181, 57-73.	0.2	2
616	Impact of next generation sequencing results on clinical management in patients with hematological disorders. <i>Leukemia and Lymphoma</i> , 2021, 62, 1702-1710.	0.6	4
617	Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. <i>Blood Advances</i> , 2022, 6, 152-164.	2.5	11
618	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.2	4
619	Targeting mitochondrial metabolism in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 530-537.	0.6	3
620	Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5026.	1.7	7
621	Harnessing multimodal data integration to advance precision oncology. <i>Nature Reviews Cancer</i> , 2022, 22, 114-126.	12.8	168
622	Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5055.	1.7	4
623	Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia. <i>Biological Chemistry</i> , 2021, 402, 1547-1564.	1.2	1
624	Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. <i>Cancers</i> , 2021, 13, 5075.	1.7	9
625	New Drugs Bringing New Challenges to AML: A Brief Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 1003.	1.1	5
626	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 95-111.	0.9	6
627	Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of <i>CDX2</i> and <i>IDH1/2</i> mutations. <i>Blood</i> , 2022, 139, 1850-1862.	0.6	28
628	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	2.2	27
629	A comprehensive approach to therapy of haematological malignancies in older patients. <i>Lancet Haematology</i> , 2021, 8, e840-e852.	2.2	17
631	Escape Mechanisms in Allosteric IDH Inhibition. , 2019, 16, .		0
632	Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. <i>Clinical Hematology International</i> , 2019, 1, 173-179.	0.7	0

#	ARTICLE	IF	CITATIONS
633	Primed for Self-Destruction: Adding Venetoclax to Azacitidine for MDS. , 2019, 16, .		0
636	Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia. Journal of the Advanced Practitioner in Oncology, 2019, 10, 494-500.	0.2	2
638	A summary of the molecular testing recommended in acute myeloid leukemia. , 2020, 4, 012-017.		2
641	Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 999-1003.	2.3	0
643	Metabolite discovery through global annotation of untargeted metabolomics data. Nature Methods, 2021, 18, 1377-1385.	9.0	107
644	TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 162-185.	2.6	22
646	Optimizing management of acute leukemia in community centers and when to refer. Hematology American Society of Hematology Education Program, 2020, 2020, 123-128.	0.9	5
647	The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutationâ€“positive relapsed/refractory acute myeloid leukemia. Cancer Medicine, 2021, 10, 797-805.	1.3	7
650	Therapy-Induced Marrow Changes. , 2020, , 713-738.		0
652	Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations. , 2020, 38, 40-43.		0
653	Adverse Cutaneous Reactions to Chemotherapeutic Agents. , 2020, , 757-795.		0
654	æ€¥æ€§æ€“é«„æ€§ç™™1/2è¡€ç—…ã@ã,²ãfŽãfç•°ã„ã•æ—°è æ²»ç™™,è—¬. Nihon Ika Daigaku Igakkai Zasshi, 2020, 16,ã88-34.		0
655	Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia. Journal of the Advanced Practitioner in Oncology, 2020, 11, 196-200.	0.2	4
656	Pediatric acute myeloid leukemias treatment: current scientific view. Oncogematologiya, 2020, 15, 10-27.	0.1	2
657	2018â€“2019 Drug Updates in Hematologic Malignancies. Journal of the Advanced Practitioner in Oncology, 2020, 11, 249-253.	0.2	0
658	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nature Communications, 2021, 12, 6436.	5.8	45
659	Identification and Preliminary Structure-Activity Relationship Studies of 1,5-Dihydrobenzo[e][1,4]oxazepin-2(3H)-ones That Induce Differentiation of Acute Myeloid Leukemia Cells In Vitro. Molecules, 2021, 26, 6648.	1.7	1
660	Ivosidenib â€“ Another Feather in the Hat of Treatment for Acute Myeloid Leukemia. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 552-554.	0.1	0

#	ARTICLE	IF	CITATIONS
661	Clinical Presentation, Diagnosis, and Classification of Acute Myeloid Leukemia. Hematologic Malignancies, 2021, , 11-55.	0.2	0
663	Management of Relapsed/Refractory Acute Myeloid Leukemia. Hematologic Malignancies, 2021, , 89-109.	0.2	0
664	Novel and Investigational Therapies in Acute Myeloid Leukemia. Hematologic Malignancies, 2021, , 133-144.	0.2	0
668	Editors' Choice How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya Journal of Medical Science, 2020, 82, 151-160.	0.6	1
670	Molecular, clinical, and prognostic implications of <i>PTPN11</i> mutations in acute myeloid leukemia. Blood Advances, 2022, 6, 1371-1380.	2.5	16
671	Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers, 2021, 13, 5608.	1.7	10
672	Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia. Cancers, 2021, 13, 5658.	1.7	3
674	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. Cancers, 2021, 13, 5722.	1.7	17
676	The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology. Therapie, 2021, , .	0.6	0
677	Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy. Nature Communications, 2021, 12, 6546.	5.8	7
678	The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients. International Journal of Biological Markers, 2021, 36, 27-35.	0.7	2
679	Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma. Liver Cancer International, 2022, 3, 17-31.	0.2	6
680	Differential impact of <i>IDH1</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 2022, 6, 1394-1405.	2.5	17
682	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	7.7	73
683	Mutant IDH Inhibits IFN- γ -TET2 Signaling to Promote Immuno-evasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discovery, 2022, 12, 812-835.	7.7	55
684	Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. Progress in Retinal and Eye Research, 2022, 89, 101030.	7.3	18
685	Exosomes in the Healthy and Malignant Bone Marrow Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1350, 67-89.	0.8	1
686	Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey. Leukemia Research Reports, 2021, 16, 100280.	0.2	1

#	ARTICLE	IF	CITATIONS
687	Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 810387.	1.3	7
688	The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Oncology</i> , 2021, 11, 793274.	1.3	4
689	Clinical development of IDH1 inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2022, 103, 102334.	3.4	18
691	Akute myeloische Leuk�mie: Therapie im Wandel. , 0, , .		1
692	Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 21-28.	1.0	3
693	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0,784314 rgBT /Over	1.0	2
694	Follow-up of patients with R/R <i>FLT3- <i> 3="" <i="" admiral="" aml="" gilteritinib="" i>mutation��positive="" in="" phase="" the="" treated="" trial.="" with="">Blood, 2022, 139, 3366-3375.</i>>	0.6	55
695	Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. <i>Cureus</i> , 2022, 14, e21018.	0.2	0
696	The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 78-84.	1.0	0
697	Azacitidine maintenance in AML post induction and posttransplant. <i>Current Opinion in Hematology</i> , 2022, 29, 84-91.	1.2	3
698	IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 12-14.	0.2	1
699	Management of drug��drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. <i>Lancet Haematology,the</i> , 2022, 9, e58-e72.	2.2	29
700	The Distribution and Significance of <i>IDH</i> Mutations in Gliomas. , 0, , .		1
701	Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering. <i>Frontiers in Oncology</i> , 2021, 11, 790299.	1.3	12
702	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	1.7	2
703	Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 796477.	1.3	0
704	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 83-124.	1.6	12
705	current knowledge on ASXL1-mutated acute myeloid leukemia. <i>Journal of Education, Health and Sport</i> , 2022, 12, 27-33.	0.0	1

#	ARTICLE	IF	CITATIONS
706	Molecular profile of <i>FLT3</i> -mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. <i>Blood Advances</i> , 2022, 6, 2144-2155.	2.5	28
707	NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 106-117.	2.3	54
708	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 203-214.	2.3	1
709	Comparison of different treatment strategies for blast-phase myeloproliferative neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	2
710	Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort. <i>European Journal of Haematology</i> , 2022, 108, 437-445.	1.1	5
711	Functional genomic approaches in acute myeloid leukemia: Insights into disease models and the therapeutic potential of reprogramming. <i>Cancer Letters</i> , 2022, 533, 215579.	3.2	2
712	Natural Killer Cell-Mediated Immunotherapy for Leukemia. <i>Cancers</i> , 2022, 14, 843.	1.7	16
713	Differentiation therapy for myeloid malignancies: beyond cytotoxicity. <i>Blood Cancer Journal</i> , 2021, 11, 193.	2.8	31
714	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 7190.	5.8	7
715	Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia. <i>Stem Cells Translational Medicine</i> , 2022, 11, 461-477.	1.6	8
716	Delivery strategies in treatments of leukemia. <i>Chemical Society Reviews</i> , 2022, 51, 2121-2144.	18.7	17
717	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i> -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. <i>JCO Precision Oncology</i> , 2022, 6, e2100197.	1.5	10
718	Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed <i>IDH1/2</i> Mutant Acute Myeloid Leukemia. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 429-441.	0.8	3
719	Treatment Pattern, Financial Burden, and Outcomes in Elderly Patients with Acute Myeloid Leukemia in Korea: A Nationwide Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2317.	1.2	2
720	Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting <i>IDH</i> -Mutations. <i>Cancers</i> , 2022, 14, 1125.	1.7	10
721	Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2362.	1.8	5
722	How I treat with maintenance therapy after allogeneic AHSCT. <i>Blood</i> , 2023, 141, 39-48.	0.6	11
723	Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!. <i>Cancers</i> , 2022, 14, 1490.	1.7	9

#	ARTICLE	IF	CITATIONS
724	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2022, 36, 1693-1696.	3.3	1
725	Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process. <i>BioEssays</i> , 2022, 44, e2100252.	1.2	12
726	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. <i>Genes and Development</i> , 2022, 36, 259-277.	2.7	19
727	Biology of IDH mutant cholangiocarcinoma. <i>Hepatology</i> , 2022, 75, 1322-1337.	3.6	20
728	New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3887.	1.8	16
729	A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1145-1158.	1.2	14
730	The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. <i>Cancer Discovery</i> , 2022, 12, 1266-1281.	7.7	67
731	<i>IDH1/2</i> mutations in acute myeloid leukemia. <i>Blood Research</i> , 2022, 57, 13-19.	0.5	6
732	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	1.7	7
733	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. <i>EJHaem</i> , 0, , .	0.4	0
734	The proteogenomic subtypes of acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 301-317.e12.	7.7	43
735	Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2863.	1.8	1
736	Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents. <i>Cancers</i> , 2022, 14, 1689.	1.7	6
737	Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives. <i>Pharmaceutics</i> , 2022, 14, 559.	2.0	6
738	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	2.0	12
739	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	3.3	19
740	Impact of <i>IDH1</i> and <i>IDH2</i> mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. <i>Blood Advances</i> , 2023, 7, 436-444.	2.5	14
742	Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. <i>Blood Reviews</i> , 2022, 55, 100950.	2.8	9

#	ARTICLE	IF	CITATIONS
743	Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies. <i>Cancer Letters</i> , 2022, 533, 215603.	3.2	6
744	Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. , 2022, 237, 108170.		9
745	Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. <i>Cell Reports Medicine</i> , 2021, 2, 100469.	3.3	21
746	Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2022, 63, 684-693.	0.6	1
747	Have we reached a molecular era in myelodysplastic syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 418-427.	0.9	23
748	Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 1058.	1.5	21
749	Treatment of AML Relapse After Allo-HCT. <i>Frontiers in Oncology</i> , 2021, 11, 812207.	1.3	16
750	Whom should we treat with novel agents? Specific indications for specific and challenging populations. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 24-29.	0.9	1
751	Decitabine Enhances Acute Myeloid Leukemia Cell Apoptosis through SH3BGRL Upregulation. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2274-2281.	0.9	1
752	Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2022, 29, 63-73.	1.2	17
753	The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence. <i>Blood Reviews</i> , 2022, 54, 100914.	2.8	8
754	Impact of cancer metabolism on therapy resistance – Clinical implications. <i>Drug Resistance Updates</i> , 2021, 59, 100797.	6.5	43
755	What to use to treat AML: the role of emerging therapies. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 16-23.	0.9	17
756	IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 83-97.	1.3	10
757	Molecular Risk Stratification using Next-generation Sequencing in Acute Myeloid Leukemia. <i>Korean Journal of Medicine</i> , 2021, 96, 493-500.	0.1	0
758	IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100560.	0.7	2
759	Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. <i>Experimental Hematology</i> , 2022, 111, 13-24.	0.2	6
760	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 1519-1531.	13.9	186

#	ARTICLE	IF	CITATIONS
761	Targeting mutations in cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	56
762	Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade. <i>Blood</i> , 2022, 139, 3752-3770.	0.6	12
763	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. <i>Nature Reviews Cardiology</i> , 2022, 19, 414-425.	6.1	23
775	SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. <i>Cell Research</i> , 2022, 32, 638-658.	5.7	19
779	Genetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes. <i>Journal of Clinical Medicine</i> , 2022, 11, 2378.	1.0	6
780	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , the, 2022, 9, e350-e360.	2.2	26
781	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. <i>Lancet Haematology</i> , the, 2022, 9, e361-e373.	2.2	25
782	Targeting IDH-Mutant Glioma. <i>Neurotherapeutics</i> , 2022, 19, 1724-1732.	2.1	13
783	The dual role of autophagy in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2022, 15, 51.	6.9	23
784	Molecular and clinical characteristics of <scp>IDH</scp> mutations in Chinese <scp>NSCLC</scp> patients and potential treatment strategies. <i>Cancer Medicine</i> , 2022, , .	1.3	1
785	Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. <i>Nature Communications</i> , 2022, 13, 2614.	5.8	9
786	N6-Methyladenosine-Related lncRNAs Are Novel Prognostic Markers and Predict the Immune Landscape in Acute Myeloid Leukemia. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	5
789	Epigenetic Genes Alterations in Metastatic Solid Tumors: Results from the Prospective Precision Medicine MOSCATO and MATCH-R Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
790	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 568-583.	1.8	10
791	Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 780-784.	1.2	1
792	Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment. <i>Current Oncology Reports</i> , 2022, 24, 1387-1400.	1.8	11
793	New Therapeutic Strategies for Adult Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 2806.	1.7	15
794	Application of precision medicine in clinical routine in haematologyâ€”Challenges and opportunities. <i>Journal of Internal Medicine</i> , 2022, 292, 243-261.	2.7	12

#	ARTICLE	IF	CITATIONS
795	CÄlenÄ; IÄ©Äba mutovanÄ© formy isocitrÄjt dehydrogenÄjzy 1 u akutnÄ-myeloidnÄ-leukemie - pÄ™ÄbÄh ivosidenibu. <i>Onkologie (Czech Republic)</i> , 2021, 14, 295-298.	0.0	0
796	Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210908.	1.1	3
797	Targeting AML in Unfit Patients: Ivosidenib/Azacitidine for <i>IDH1</i>-mutated AML. , 2022, 19, .		0
798	Unbiased decision-making for acute myeloid leukemia still needed. <i>Haematologica</i> , 0, , .	1.7	1
799	Resistance to targeted therapies: delving into FLT3 and IDH. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	9
800	2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies. <i>Biomedicines</i> , 2022, 10, 1359.	1.4	8
801	Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 169-185.	1.0	1
802	Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	0.6	27
803	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	0
804	Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
805	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	1.7	0
806	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. <i>Leukemia</i> , 2022, 36, 1951-1960.	3.3	9
807	Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. <i>Haematologica</i> , 2023, 108, 34-41.	1.7	2
809	Cardio-Onco-Metabolism â€œ Metabolic vulnerabilities in cancer and the heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 171, 71-80.	0.9	2
810	Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors. <i>Nature Cancer</i> , 2022, 3, 852-865.	5.7	37
811	Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas. <i>Cancers</i> , 2022, 14, 2891.	1.7	8
812	Myelodysplastic Syndrome: Diagnosis and Screening. <i>Diagnostics</i> , 2022, 12, 1581.	1.3	4
813	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. <i>Journal of Internal Medicine</i> , 2022, 292, 262-277.	2.7	7

#	ARTICLE	IF	CITATIONS
814	AACR Project GENIE: 100,000 Cases and Beyond. <i>Cancer Discovery</i> , 2022, 12, 2044-2057.	7.7	27
815	Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	14
816	Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
817	Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. <i>International Journal of Hematology</i> , 2022, 116, 330-340.	0.7	20
818	A tubulin binding molecule drives differentiation of acute myeloid leukemia cells. <i>IScience</i> , 2022, 25, 104787.	1.9	3
820	Metabolic analysis as a driver for discovery, diagnosis, and therapy. <i>Cell</i> , 2022, 185, 2678-2689.	13.5	51
821	Venetoclax Plus Gilteritinib for <i>FLT3</i> -Mutated Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4059.	0.8	73
822	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
823	Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 850-864.e9.	7.7	82
824	In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge. <i>Journal of Clinical Medicine</i> , 2022, 11, 4283.	1.0	0
825	Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. <i>European Journal of Cancer</i> , 2022, 173, 133-145.	1.3	1
826	Proteomic Profiling Identifies Specific Leukemic Stem Cell-Associated Protein Expression Patterns in Pediatric AML Patients. <i>Cancers</i> , 2022, 14, 3567.	1.7	2
827	Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. <i>Life</i> , 2022, 12, 1135.	1.1	6
828	Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies. <i>Biomedicines</i> , 2022, 10, 1974.	1.4	9
829	A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 251-265.	1.1	0
830	Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper. <i>British Journal of Haematology</i> , 2022, 199, 205-221.	1.2	2
831	Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. <i>Blood Reviews</i> , 2023, 57, 100996.	2.8	12
832	CHIPing away the progression potential of CHIP: A new reality in the making. <i>Blood Reviews</i> , 2023, 58, 101001.	2.8	6

#	ARTICLE	IF	CITATIONS
833	Single-cell genomics in AML: extending the frontiers of AML research. <i>Blood</i> , 2023, 141, 345-355.	0.6	14
834	Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
835	Precision Medicine in Myeloid Malignancies: Hype or Hope?. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 217-227.	1.2	3
836	Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. <i>Archives of Toxicology</i> , 2022, 96, 3265-3277.	1.9	3
837	Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. <i>Cell Reports</i> , 2022, 40, 111182.	2.9	5
838	Advances in the pharmacological management of acute myeloid leukemia in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1535-1543.	0.9	1
839	Chasing leukemia differentiation through induction therapy, relapse and transplantation. <i>Blood Reviews</i> , 2023, 57, 101000.	2.8	2
840	Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and <i>IDH1</i> R132C mutation. <i>Leukemia and Lymphoma</i> , 2022, 63, 3000-3003.	0.6	1
841	Leukemias, Lymphomas, and Plasma Cell Disorders. , 2023, , 237-300.		0
842	Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	15
843	Evaluation of two new highly multiplexed <sc>PCR</sc> assays as an alternative to next-generation sequencing for <i>IDH1</i> /2 </i> mutation detection. <i>Molecular Oncology</i> , 0, , .	2.1	0
844	Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. <i>Leukemia Research</i> , 2022, 122, 106946.	0.4	0
845	Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. <i>Leukemia Research</i> , 2022, 122, 106942.	0.4	4
846	Pyridine ring as an important scaffold in anticancer drugs. , 2023, , 375-410.		1
847	Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	2
848	Oncometabolites, epigenetic marks, and DNA repair. , 2022, , 191-202.		0
849	Neurologic complications of oncologic therapy. , 2022, , 131-155.		0
850	Targeting Metastatic Disease: Challenges and New Opportunities. , 2022, , 51-68.		0

#	ARTICLE	IF	CITATIONS
851	Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. <i>Current Oncology</i> , 2022, 29, 6245-6259.	0.9	17
852	Accelerated and blast phase myeloproliferative neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101379.	0.7	5
853	Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1033-e1049.	0.2	0
854	A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges. <i>Cancers</i> , 2022, 14, 4166.	1.7	3
855	Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. <i>Cancer</i> , 2022, 128, 3880-3887.	2.0	5
856	Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	8
857	Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	6
858	Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness. <i>Cancer Research</i> , 2022, 82, 4325-4339.	0.4	7
859	Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. <i>Blood Advances</i> , 2022, 6, 5857-5865.	2.5	22
860	A New Dancing Partner for Venetoclax: Gilteritinib. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
861	Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia. <i>Journal of Personalized Medicine</i> , 2022, 12, 1607.	1.1	2
862	Updates on the Management of Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 4756.	1.7	5
863	Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	3
864	Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
872	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
873	Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
874	Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. <i>Leukemia and Lymphoma</i> , 2023, 64, 188-196.	0.6	3
875	Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. <i>Leukemia and Lymphoma</i> , 2023, 64, 273-282.	0.6	0

#	ARTICLE	IF	CITATIONS
877	Recommendations for laboratory testing of <sc>UK</sc> patients with acute myeloid leukaemia. British Journal of Haematology, 2023, 200, 150-159.	1.2	6
878	Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. Cancer Discovery, 2023, 13, 170-193.	7.7	6
879	EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment. Blood Advances, 2023, 7, 1577-1593.	2.5	3
881	Lower intensity regimens for acute myeloid leukemia: opportunities and challenges. Leukemia and Lymphoma, 2023, 64, 66-70.	0.6	0
882	Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. Expert Review of Hematology, 2022, 15, 973-986.	1.0	1
883	Resistance to targeted therapies in acute myeloid leukemia. Clinical and Experimental Metastasis, 2023, 40, 33-44.	1.7	3
884	Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia. Leukemia Research, 2022, 123, 106970.	0.4	5
885	Significance of Gene Diagnosis in Acute Myeloid Leukemia with the Emergence of New Molecular Target Drug Treatment. Journal of Nippon Medical School, 2022, 89, 470-478.	0.3	1
886	Somatic <i>IDH1</i> Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1215-1223.	1.8	1
887	Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer Journal, 2022, 12, .	2.8	9
888	Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematology,the, 2023, 10, e46-e58.	2.2	41
890	Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia. Journal of Geriatric Oncology, 2023, 14, 101403.	0.5	1
891	Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability. Cancer Discovery, 2023, 13, 496-515.	7.7	14
892	Advances and Future Goals in Acute Myeloid Leukaemia Therapy. Touch Reviews in Oncology & Haematology, 2022, 18, 130.	0.1	0
893	A new player in IDH1 mutated myeloid neoplasias. Lancet Haematology,the, 2023, 10, e7-e8.	2.2	0
894	Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered <i>Runx1</i> splicing. NAR Cancer, 2022, 4, .	1.6	3
895	Hypomethylating agent-based therapies in older adults with acute myeloid leukemia â€“ A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. Journal of Geriatric Oncology, 2023, 14, 101406.	0.5	1
896	Moving toward individualized target-based therapies in acute myeloid leukemia. Annals of Oncology, 2023, 34, 141-151.	0.6	9

#	ARTICLE	IF	CITATIONS
897	Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
898	Antitumor pharmacological research in the era of personalized medicine. Acta Pharmacologica Sinica, 2022, 43, 3015-3020.	2.8	4
899	Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition. International Journal of Molecular Sciences, 2022, 23, 14706.	1.8	0
900	Role of Biomarkers in the Management of Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2022, 23, 14543.	1.8	3
902	Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms. Journal of Molecular Diagnostics, 2023, 25, 87-93.	1.2	3
903	Cancer epigenetics in clinical practice. Ca-A Cancer Journal for Clinicians, 2023, 73, 376-424.	157.7	43
905	The path to venetoclax resistance is paved with mutations, metabolism, and more. Science Translational Medicine, 2022, 14, .	5.8	6
906	Increased PD-1+Foxp3+ T cells associate with poor overall survival for patients with acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	3
907	Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia, 2023, 37, 550-559.	3.3	6
908	Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis. Trends in Cell Biology, 2023, 33, 455-462.	3.6	6
909	Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia and Lymphoma, 2023, 64, 454-461.	0.6	1
910	Is induction of Hypomethylation with Ivosidenib and 5-Azacitidine curative regimen against IDH1-mutated Acute Myeloid Leukemia?. Anti-Cancer Agents in Medicinal Chemistry, 2022, 23, .	0.9	0
911	Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, 405-422.	2.5	1
912	Metabolic reprogramming of cancer as a therapeutic target. Biochimica Et Biophysica Acta - General Subjects, 2023, 1867, 130301.	1.1	2
913	Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood, 2023, 141, 1610-1625.	0.6	25
914	Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical Cancer Research, 2023, 29, 878-887.	3.2	3
915	Conventional and emerging treatments of astrocytomas and oligodendrogliomas. Journal of Neuro-Oncology, 2023, 162, 471-478.	1.4	3
916	Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes. Cancer Management and Research, 0, Volume 14, 3527-3538.	0.9	1

#	ARTICLE	IF	CITATIONS
917	Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. <i>Blood</i> , 2023, 141, 1119-1135.	0.6	7
918	Is it the time to integrate novel sequencing technologies into clinical practice?. <i>Current Opinion in Hematology</i> , 0, Publish Ahead of Print, .	1.2	0
919	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
920	Current Understanding of DDX41 Mutations in Myeloid Neoplasms. <i>Cancers</i> , 2023, 15, 344.	1.7	6
921	Chromatin mutations in pediatric high grade gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
922	Acute myeloid leukemia: 2023 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2023, 98, 502-526.	2.0	58
923	Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America. <i>Hematology</i> , 2023, 28, .	0.7	0
924	The roles of IDH1 in tumor metabolism and immunity. <i>Future Oncology</i> , 2022, 18, 3941-3953.	1.1	1
925	Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 0, .	1.2	0
926	Accelerated Phase of MPN: What It Is and What to Do About It. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.2	0
927	SLC25A1-associated prognostic signature predicts poor survival in acute myeloid leukemia patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
928	Distinct and opposite effects of leukemogenic <i>Idh</i> and <i>Tet2</i> mutations in hematopoietic stem and progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	7
929	Case report: Sustained complete remission with ivosidenib in a patient with relapsed, IDH1-mutated acute leukemia. , 0, 2, .		0
930	Dermatologic complications in transplantation and cellular therapy for acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101464.	0.7	0
931	Highly Recurrent IDH1 Mutations in Prostate Cancer With Psammomatous Calcification. <i>Modern Pathology</i> , 2023, 36, 100146.	2.9	2
932	Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1</i> and <i>IDH2</i> -mutant Glioma. <i>Cancer Research Communications</i> , 2023, 3, 192-201.	0.7	2
933	An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2023, 16, 109-119.	1.0	1
934	Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory <i>IDH1</i> -mutated AML. <i>Blood Advances</i> , 2023, 7, 3117-3127.	2.5	26

#	ARTICLE	IF	CITATIONS
935	Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. <i>Haematologica</i> , 2023, 108, 342-352.	1.7	6
936	The clinical impact of the molecular landscape of acute myeloid leukemia. <i>Haematologica</i> , 2023, 108, 308-320.	1.7	22
937	The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1438-1466.	5.7	3
938	Oncogenic <i>IDH1</i> Mutation Imparts Therapeutically Targetable Metabolic Dysfunction in Multiple Tumor Types. <i>Cancer Discovery</i> , 2023, 13, 266-268.	7.7	0
939	Partial response in non-resectable adenocarcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. <i>BMJ Case Reports</i> , 2023, 16, e251936.	0.2	0
940	Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. <i>Blood Reviews</i> , 2023, 60, 101056.	2.8	2
941	Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. <i>Cell Reports Medicine</i> , 2023, 4, 100940.	3.3	4
942	Clinical utility of genomic profiling of <i>AML</i> using paraffin-embedded bone marrow clots: <i>HM-SCREEN</i> Japan 01. <i>Cancer Science</i> , 2023, 114, 2098-2108.	1.7	3
943	Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
944	Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). <i>Leukemia</i> , 2023, 37, 799-806.	3.3	11
945	Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center. <i>World Journal of Oncology</i> , 2023, 14, 40-50.	0.6	3
946	Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using Hydrogen-Deuterium Exchange Mass Spectrometry. <i>Biochemistry</i> , 2023, 62, 1145-1159.	1.2	3
948	Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy. <i>Journal of Leukocyte Biology</i> , 2023, 113, 518-524.	1.5	1
949	Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4790.	1.8	5
950	Management of Newly Diagnosed Acute Myeloid Leukemia in Older Adults. , 0, , .		0
951	Non-intensive acute myeloid leukemia therapies for older patients. <i>Expert Review of Hematology</i> , 2023, 16, 171-180.	1.0	2
952	Berberine targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia with IDH1 mutation. <i>Chinese Journal of Natural Medicines</i> , 2023, 21, 136-145.	0.7	1
953	Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. <i>Cancers</i> , 2023, 15, 1617.	1.7	4

#	ARTICLE	IF	CITATIONS
954	Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5018.	1.8	7
955	DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 745.	3.8	41
956	Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). <i>Blood Reviews</i> , 2023, 60, 101072.	2.8	7
957	The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. <i>Nature</i> , 2023, 615, 920-924.	13.7	74
958	Clinicopathologic Features of <i>IDH2</i> -Mutated Myeloid Neoplasms. <i>American Journal of Clinical Pathology</i> , 0, .	0.4	0
959	An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6031.	1.8	1
960	Recent advances in targeted therapies in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	23
963	Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i> -Mutated Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2023, 29, 2034-2042.	3.2	8
964	A review of treatment options employed in relapsed/refractory AML. <i>Hematology</i> , 2023, 28, .	0.7	6
965	Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. <i>Leukemia</i> , 2023, 37, 1234-1244.	3.3	13
966	Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. <i>Cancer</i> , 2023, 129, 2321-2330.	2.0	2
967	Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials. <i>Leukemia Research</i> , 2023, 129, 107077.	0.4	4
968	Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Clinical Hematology International</i> , 2023, 5, 143-154.	0.7	7
969	Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine. <i>Seminars in Diagnostic Pathology</i> , 2023, 40, 172-181.	1.0	1
970	Targeted therapy. , 2023, , 205-411.		0
973	Epigenetic targeted therapies in hematological malignancies. , 2023, , 213-236.		0
974	Epigenetic therapy in lung cancer. , 2023, , 237-274.		0
991	Chronic Myelomonocytic Leukaemia: A Three-Hit Malignancy. , 2023, , 153-177.		0

#	ARTICLE	IF	CITATIONS
993	Targeting the undruggable: menin inhibitors ante portas. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9451-9459.	1.2	3
1009	Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape. Indian Journal of Pediatrics, 0, , .	0.3	1
1017	Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	0
1028	Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	7
1035	Epigenetic biomarkers. , 2024, , 207-257.		0
1038	Precision Medicine. , 2023, , 199-214.		0
1042	Management of Relapsed or Refractory AML. , 2023, , 129-132.		0
1043	Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. , 2023, , 119-128.		0
1044	Frontline Management of Acute Myeloid Leukaemia Eligible for Intensive Chemotherapy. , 2023, , 91-110.		0
1045	Role of IDH1/IDH2 Inhibitors in AML. , 2023, , 147-149.		0
1062	DNA Methylation Alterations in Acute Myeloid Leukemia: Therapeutic Potential. , 2023, , .		0
1070	Differentiating Acute Myeloid Leukemia Stem Cells/Blasts. , 2024, , .		0
1073	Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation. Oncology and Therapy, 2024, 12, 57-72.	1.0	0
1078	Regulation of tumor microenvironment by nutrient trafficking. , 2024, , 297-308.		0